PureTech Health pinches Arix boss as new chief portfolio officer

Biotherapeutics company PureTech Health, which develops medicines to treat serious diseases, has appointed the boss of Arix Bioscience as its new chief portfolio officer.

Robert Lyne, who has a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience, will join the company in January 2024.

"We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients," said Daphne Zohar, PureTech's founder and chief executive.

Lyne joins the group from Arix Bioscience, a venture capital firm that invests in innovative biotech companies, where he served as general council and chief operating officer before becoming chief executive in 2021. He began his career as a lawyer.

Zohar said: "[Lyne's] extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech's own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties."